Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

The Lancet

DOI: 10.1016/s0140-6736(18)31791-4 Full text (OA) OpenAlex

Authors 0

Author list not loaded yet.

Cited by 16 stored of 593

Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
2025 Neuro-Oncology article Medicine Glioma Diagnosis and Treatment Open access

76

citations
The ATLAS/NOA-29 study protocol: a phase III randomized controlled trial of anterior temporal lobectomy versus gross-total resection in newly-diagnosed temporal lobe glioblastoma
2025 BMC Cancer article Medicine Glioma Diagnosis and Treatment Open access

1

citations
Functional connectivity between tumor region and resting-state networks as imaging biomarker for overall survival in recurrent gliomas diagnosed by O-(2-[18F]fluoroethyl)- l -tyrosine PET
2025 Neuro-Oncology Advances article Neuroscience Functional Brain Connectivity Studies Open access

4

citations
Health-Related Quality of Life in Neuro-Oncology
2025 Elsevier eBooks book-chapter Medicine Cancer survivorship and care

0

citations
Temozolomide and Lomustine Induce Tissue Factor Expression and Procoagulant Activity in Glioblastoma Cells In Vitro
2023 Cancers article Medicine Blood Coagulation and Thrombosis Mechanisms Open access

9

citations
Data from Diagnosis of Pseudoprogression Following Lomustine–Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET
2023 other Medicine Glioma Diagnosis and Treatment Open access

0

citations
Data from Diagnosis of Pseudoprogression Following Lomustine–Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET
2023 other Medicine Glioma Diagnosis and Treatment Open access

0

citations
Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics—a prospective multicenter cohort study
2022 BMC Medical Genomics article Medicine Glioma Diagnosis and Treatment Open access

7

citations
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial
2022 Trials article Medicine Glioma Diagnosis and Treatment Open access

37

citations
Quality of Life and Brain Cancer
2022 Springer eBooks book-chapter Medicine Cancer survivorship and care

1

citations
Advances in the management of glioblastoma
2021 Journal of Neurology Neurosurgery & Psychiatry article Medicine Glioma Diagnosis and Treatment

132

citations
Diagnosis of Pseudoprogression Following Lomustine–Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET
2021 Clinical Cancer Research article Medicine Glioma Diagnosis and Treatment

39

citations
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
2020 Nature Reviews Clinical Oncology review Medicine Glioma Diagnosis and Treatment Open access cited by 4 patents

2,019

citations
Early Treatment Response Assessment Using 18 F-FET PET Compared with Contrast-Enhanced MRI in Glioma Patients After Adjuvant Temozolomide Chemotherapy
2020 Journal of Nuclear Medicine article Medicine Glioma Diagnosis and Treatment

51

citations
A Preliminary Study on Machine Learning-Based Evaluation of Static and Dynamic FET-PET for the Detection of Pseudoprogression in Patients with IDH-Wildtype Glioblastoma
2020 Cancers article Medicine Glioma Diagnosis and Treatment Open access

40

citations
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
2020 Neuro-Oncology article Medicine Glioma Diagnosis and Treatment Open access cited by 1 patent

1,195

citations

16 results

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

Authors 0

Cited by 16 stored of 593

References 0